1,751 Followers on Owler
bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer...
Read morebluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer...
Read more
News
Jan 22, 2023
Nasdaq
bluebird bio: Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Jan 19, 2023
BioSpace
bluebird bio: bluebird Seeks Funding Through 2024 with IPO
Jan 18, 2023
Endpoints News
bluebird bio: Bluebird hopes to raise upwards of $100M by selling shares
Jan 09, 2023
PMLiVE
bluebird bio: bluebird bio sells second FDA priority review voucher for $95m
Jan 06, 2023
BioPharma Dive
bluebird bio: Bluebird bolsters balance sheet with sale of second regulatory fast pass
Dec 12, 2022
BioPharma Dive
bluebird bio: Gene therapy approval won, Bluebird takes on next challenge: selling it
Dec 10, 2022
centralcharts
Press Release: bluebird bio : New Data from bluebird bio's Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
Dec 01, 2022
PMLiVE
bluebird bio: bluebird bio sells Rare Pediatric Disease Priority Review Voucher for $102m
Dec 01, 2022
The Business Journals: Boston
bluebird bio: Bluebird gets a much-needed $102M
Nov 30, 2022
BioPharma Dive
bluebird bio: Bluebird sells regulatory fast pass to Argenx for $102M
bluebird bio Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to bluebird bio?
bluebird bio Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$5.1M
bluebird bio's revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 4.7B. Over the last two quarters, bluebird bio's revenue has decreased by 21.9%. Specifically, in Q2 2022's revenue was $1.5M; in Q1 2022, it was $1.9M.
bluebird bio News
bluebird bio Press Releases
bluebird bio Videos
bluebird bio Headquarters
bluebird bio Summary
ABOUT
Overview
bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer. bluebird bio was founded in 1992. bluebird bio's headquarters is located in Cambridge, Massachusetts, USA 02142. bluebird bio's CEO, Andrew Obenshain...CEO
bluebird bio's CEO, Andrew Obenshain, currently has an approval rating of 58%. bluebird bio's primary competitors are Sangamo, Intellia & CRISPR.Website
bluebirdbio.comCompetitors
View 15 bluebird bio competitors here.Acquisitions
View 1 companies acquired by bluebird bio here.Investments
Recent investment data cannot be found related to bluebird bioFrequently Asked Questions about bluebird bio
When was bluebird bio founded?
bluebird bio was founded in 1992Who is bluebird bio's CEO?
bluebird bio's CEO is Andrew ObenshainHow much revenue does bluebird bio generate?
bluebird bio generates $5.1M in revenueHow much funding does bluebird bio have?
bluebird bio has historically raised $526.4M in funding
Where is bluebird bio's headquarters?
bluebird bio's headquarters is in Cambridge Massachusetts, USAHow many employees does bluebird bio have?
bluebird bio has 520 employeesWhat sector does bluebird bio operate in?
bluebird bio is in BiotechnologyWho are bluebird bio's competitors?
bluebird bio's top competitors are Sangamo, Intellia, CRISPR